SV News
9 August 2022Portfolio NewsOn heels of Parkinson’s readout, Cerevance enters Alzheimer’s discovery deal with Merck
6 July 2022Portfolio NewsNitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives- 21 June 2022Portfolio NewsQurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board
31 May 2022Portfolio NewsTransine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development
27 April 2022Portfolio NewsAviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia- 19 April 2022Portfolio NewsCerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
- 5 April 2022Portfolio NewsNitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research
- 31 March 2022Portfolio NewsCerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
20 March 2022SV NewsFast-track dementia to curb it like Covid
19 March 2022Portfolio NewsLoQus23: going upstream to slow Huntington’s disease- 18 March 2022Portfolio NewsNitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference
- 2 March 2022Portfolio NewsCaraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD
